Two-year results of intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation

Abstract

Aim To clarify the 2-year efficacy of ranibizumab for patients with polypoidal choroidal vasculopathy (PCV) with recurrent or residual exudation from branching vascular networks after previous photodynamic therapy (PDT). Methods We retrospectively reviewed 26 eyes of 26 Japanese patients (22 men, 4 women) in this pilot study. All eyes had PCV with complete regression of polypoidal lesions resulting from PDT detected by indocyanine green angiography (ICGA), but recurrent or residual leakage from branching vascular networks on fluorescein angiography and evidence of persistent fluid on optical coherence tomography (OCT). Three consecutive intravitreal injections of ranibizumab (0.5 mg/0.05 ml) were administered to all eyes. Results The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly from 0.55 at baseline to 0.35 at 12 months (Po0.0001) and 0.43 at 24 months (P ¼ 0.0012). The mean increases in the BCVA 12 and 24 months after baseline were 1.95 and 1.23 lines, respectively. The mean central retinal thickness significantly decreased from 295 mm at baseline to 189 mm at 12 months (Po0.0038) and 163 mm at 24 months (Po0.001). The mean numbers of intravitreal ranibizumab (IVR) injections at months 12 and 24, including the initial treatments, were 5.8 and 8.8, respectively. Five (19.2%) eyes had recurrent polypoidal lesions on ICGA at a mean of 15.7 months after baseline. At month 24, OCT showed no exudation in 17 (65.4%) of the 26 eyes. No adverse events developed.Conclusions IVR injections maintained or improved the VA and retinal thickness at 24 months in eyes with PCV with recurrent or residual exudation from branching vascular networks after previous PDT.

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps

“…Saito et al . 10 reported that ranibizumab was efficacious in patients with PCV with recurrent or residual exudation from BVN after previous PDT. However, the efficacy of aflibercept in recurrent or refractory cases has not been determined.…”

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population

“…[4][5][6][7][8][9][10][11][12][13][14] In a previous study 7 (ClinicalTrials.gov identifier: NCT00837330), we evaluated intravitreal ranibizumab 0.3-and 0.5-mg monotherapy in 20 eyes of non-Asian patients with PCV. Ranibizumab (0.3-and 0.5-mg groups pooled) was well tolerated and resulted in improved best-corrected visual acuity (BCVA; +1.2 Snellen lines at months 12 and 24) and reduced center point thickness (−53 and − 67 μm at months 12 and 24, respectively) in the majority of eyes.…”